Global Human Growth Hormone Market by Application (Turner Syndrome, Growth Hormone Deficiency) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global human growth hormone market was valued at USD4.6 billion in 2019. It is expected to grow 8.2% during the forecast period. Market drivers include strong R&D, strong product portfolios, investments by market players, and increased government initiatives.

The peptide hormone human growth hormone (HGH), also called somatotropin and responsible for cell reproduction and growth stimulation in humans, is essential for human development. A pituitary gland that does not produce enough hGH can cause growth hormone (GH) deficiencies in humans. Subcutaneous injections of recombinant human Growth Hormone can treat this deficiency. Prader-Willi Syndrome and Turner syndrome may also lead to growth hormone deficiency. This can cause delayed puberty, shorter height, and other genetic conditions.

The American Academy of Pediatrics published data showing that growth hormone deficiency in humans is rare and affects less then one in 3,000 to one million children in the United States. Currently, hGH is widely abused as an anti-aging treatment in older adults and as a performance-enhancing anabolic drug by bodybuilders and athletes. However, HGH is a controlled substance as per the USFDA and has not been approved for anti-aging and performance-enhancing indications.

Market for human growth hormones will be driven by a strong product pipeline and extensive R&D activities to develop novel therapies. Novo Nordisk, for example, presented Phase II data from its investigational GH therapy Somapacitan in September 2018. This is indicated for the treatment and prevention of growth hormone deficiency. Ascendis Pharma A/S also published Phase III results from its TransCon HGH clinical trial, which was indicated for the treatment of pediatric growth hormone deficiencies. Several key players, including Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences, are also involved in R&D activities to develop novel human growth hormone therapies.

The market will be driven by initiatives taken by both government and private organizations to raise awareness about GH deficiencies as well as human growth hormone treatment. The International Coalition of Organizations Supporting Endocrinine Patients (ICOSEP), a U.S.-based non-profit charitable organization, celebrates International Children's Growth Awareness Day every year to raise awareness about early diagnosis and treatment of growthhormone disorders in children.

The market's progress may be impeded by the high cost of hGH treatments and other adverse effects. According to UPMC Children's Hospital of Pittsburgh (UPMC Children's Hospital of Pittsburgh), side effects of GH hormone therapy could include joint pain, swelling or hives, and knee or hip pain.

Application Insights

The GH deficiency segment dominated the market in 2019 and will continue to dominate the market over the forecast period. This is due to increased awareness regarding early diagnosis and treatment for GH deficiency in people and the introduction novel drugs into the hGH market. Ascendis Pharma A/S was granted Orphan Designation by the European Commission (EC), in October 2018 for TransCon hGH, an investigational long-acting GH treatment for humans. This is indicated for treating pediatric GH deficiency.

Ferring Pharmaceuticals Inc. was also approved by the USFDA in January 2018 for Zomacton (somatropin), a recombinant HGH that is indicated for treatment of adults suffering from GH deficiency. Due to increasing supply of pipeline drugs, the market for GH deficiency is further divided into two segments: pediatric GH and adult GH. In October 2019, Pfizer Inc., along with its partner OPKO Health Inc., announced that the Phase III study on Somatrogon in prepubertal children with hGH had met its primary endpoint. It was non-inferior to daily somatropin.

Turner's syndrome was the second-largest segment in the 2019 market and will continue to grow as a profitable market over the forecast period. This is due to the increasing awareness of Turner syndrome by both public and private organizations. Turner Syndrome Society of the United States (UK), Turner Syndrome Society of the United States (USA) and Turner Syndrome Foundation organize "Turner Syndrome Awareness Month" each February to raise awareness and create a national campaign.

Distribution Channel Insights

The distribution channel is what separates the market for human growth hormone into specialty pharmacy, online pharmacy and retail pharmacy. In 2019, the hospital pharmacy segment accounted for a large share. The hospital pharmacy segment accounted for a significant share of 2019's total. This is due to an increase in hospital visits and awareness about GH deficiencies among people and treatment. According to the Children's Hospital of Philadelphia, prescriptions for growth hormone have increased from 5.1 per 10,000 beneficiaries in 2001 up to 14.6 per 10,000 in 2016.

Due to the high penetration in pharmacies in developed countries like North America and Europe, the online pharmacy segment will see a significant CAGR during the forecast period. The segment will continue to grow due to the rising popularity of online pharmacies within emerging economies like India and China.

Regional Insights

North America accounts for the largest percentage of global healthcare spending. This is due to factors like a favorable reimbursement system, established healthcare infrastructure, substantial government initiatives and increasing healthcare awareness. The North American market is supported by the presence of key players. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., are key U.S. players offering a broad range of human GH treatments in the region.

The Asia Pacific region is expected to experience a substantial CAGR during the forecast period. The key players are focused on gaining market share in the potential Asian countries such as Japan, China and South Korea by gaining approvals and launching new products. Novo Nordisk A/S, an American pharmaceutical company based in Denmark, began the third phase of its HGH somapacitan clinical trial in Japan in March 2017.

Market Share in Human Growth Hormones

Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Sandoz International GmbH, (Novartis AG); Merck KGaA, Genentech, Inc., (Roche); Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd., and Ipsen are some of the major players in this market. Many companies are focused on long-acting hormones for human growth.

Major companies in the market are using mergers, partnerships and acquisitions to increase their geographical reach and access to their solutions. Novo Nordisk and Strongbridge Biopharma, for example, signed an agreement in October 2018 to acquire rights to MACRILEN in Canada and the U.S. MACRILEN (macimorelin), the FDA's first and only approved oral drug for adult growth hormone deficiencies diagnosis, is MACRILEN.

Human Growth Hormones Market Report Scope

The Report Covers Certain Segments

This report forecasts revenue growth at the global, regional and country level. It also provides analysis of industry trends and potential opportunities in each sub-segment from 2016-2027. Grand View Research has divided the global market for human growth hormones on the basis, of distribution channel and of region.

• App Outlook (Revenue USD Million, 2016-2027)

  • Growth Hormone (GH) Deficiency

    • Adult GH Deficiency

    • Pediatric GH Deficiency

  • Turner Syndrome

  • Idiopathic Short Stature

  • Prader-Willi Syndrome

  • Gestational Age: Small

  • Other

• Distribution Channel Outlook (Revenue USD Million, 2016-2027)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online pharmacy

  • Specialty Pharmacy

• Regional Outlook (Revenue USD Million, 2016-2027)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

    • Spain

    • France

    • Italy

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Singapore

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

These are the most frequently asked questions about this report

b. Global human growth hormone market was valued at USD 3.6 billion in 2019, and is forecast to grow to USD 3.7 billion by 2020.

b. Global human growth hormone markets are expected to grow at 8.2% per year between 2020 and 2027, reaching USD 8.5 billion in 2027.

b. With a 35.9% share in 2019, North America dominated global human growth hormone markets. This can be attributed to factors like favorable reimbursement, established healthcare infrastructure, significant government initiative, and growing healthcare awareness.

b. Novo Nordisk A/S, Pfizer, Inc, Eli Lilly and Company, Sandoz International GmbH, Novartis AG; Merck KGaA, Genentech, Inc (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, and Ipsen are some of the major players in the human growthhormone market.

b. b.

Up Market Research published a new report titled “Human Growth Hormone Market research report which is segmented by Application (Turner Syndrome, Growth Hormone Deficiency), By Players/Companies Novo Nordisk A/S; Pfizer, Ltd; and Ipsen, Inc; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Human Growth Hormone Market Report Segments:

The market is segmented by Application (Turner Syndrome, Growth Hormone Deficiency).

Human Growth Hormone Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Human Growth Hormone Market

Overview of the regional outlook of the Human Growth Hormone Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Human Growth Hormone Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Human Growth Hormone Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Turner Syndrome

                2. Growth Hormone Deficiency

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Human Growth Hormone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Human Growth Hormone Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.